Acadia Pharmaceuticals (ACAD) Revenue (2010 - 2026)

Acadia Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $268.1 million for Q1 2026.

• In Q1 2026, Revenue rose 9.72% year-over-year to $268.1 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 9.93% YoY), while the FY2025 annual figure was $1.1 billion, up 11.87% from the prior year.
• Revenue was $268.1 million for Q1 2026 at Acadia Pharmaceuticals, down from $284.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $284.0 million in Q4 2025 to a low of $115.5 million in Q1 2022.
• Historically, Revenue has averaged $208.3 million across 5 years, with a median of $231.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue decreased 0.68% in 2022, then surged 73.75% in 2024.
• A 5-year view of Revenue shows it stood at $136.5 million in 2022, then soared by 69.27% to $231.0 million in 2023, then rose by 12.36% to $259.6 million in 2024, then increased by 9.39% to $284.0 million in 2025, then declined by 5.61% to $268.1 million in 2026.
• The last three Revenue figures came in at $268.1 million (Q1 2026), $284.0 million (Q4 2025), and $278.6 million (Q3 2025), per Business Quant data.